The historical rank and industry rank for JFL Life Sciences's OCF Margin % or its related term are showing as below:
NSE:JFLLIFE'
s OCF Margin % Range Over the Past 10 Years
Min: -21.18 Med: -4.3 Max: 18.06
Current: -4.3
During the past 7 years, the highest OCF Margin % of JFL Life Sciences was 18.06%. The lowest was -21.18%. And the median was -4.30%.
NSE:JFLLIFE's OCF Margin % is ranked worse than 78.24% of 956
companies
in the Drug Manufacturers industry
Industry Median: 9.985
vs NSE:JFLLIFE: -4.30
JFL Life Sciences OCF Margin % Related Terms
JFL Life Sciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a OCF Margin % of -4.30% as of Mar. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on JFL Life Sciences and its competitors. According to the industry distribution chart, JFL Life Sciences ranks #748 out of 956 companies in the Drug Manufacturers industry, placing it in the top 78.2%.
Is JFL Life Sciences' OCF Margin % too high?
JFL Life Sciences' current OCF Margin % is -4.30%. Based on the distribution chart, JFL Life Sciences ranks #748 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, JFL Life Sciences has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #748 out of 956 companies for OCF Margin %. This places JFL Life Sciences in the lower half of its industry. The industry median OCF Margin % is 9.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.99, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current OCF Margin % is -4.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.55, compared to a current price of ₹9.05 — trading 74.5% below its estimated fair value. The current OCF Margin % is -4.30%. JFL Life Sciences' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current OCF Margin % is -4.30% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹9.05 is trading 74.5% below its estimated GF Value™ of ₹35.55.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
OCF Margin %: -4.30%
GF Value™: ₹35.55 vs. price of ₹9.05 (74.5% below fair value)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
65GF Score
Get the complete analysis for NSE:JFLLIFE
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 